Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott J Rodig

Showing results (71-80 of 293) with videos related to

Pageof 30
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 28, 2023
Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 TherapyElizabeth I Buchbinder, Kathleen L Pfaff, Madison M Turner, et al.
American Journal of Clinical Pathology|February 3, 2016
MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical PracticeMichael J Kluk, Caleb Ho, Hongbo Yu, et al.
Cancer Cell|August 18, 2012
Synergy between PI3K signaling and MYC in Burkitt lymphomagenesisSandrine Sander, Dinis P Calado, Lakshmi Srinivasan, et al.
Plos One|April 19, 2012
Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomasMichael J Kluk, Bjoern Chapuy, Papiya Sinha, et al.
Cancer Medicine|October 18, 2016
A phase I trial of panobinostat (LBH589) in patients with metastatic melanomaNageatte Ibrahim, Elizabeth I Buchbinder, Scott R Granter, et al.
Blood|August 21, 2012
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemiaChristopher J Ott, Nadja Kopp, Liat Bird, et al.
Haematologica|September 1, 2019
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomasLinfeng Chen, Jing Ouyang, Kirsty Wienand, et al.
Plos One|November 13, 2012
Next-generation cDNA screening for oncogene and resistance phenotypesNobuaki Shindoh, Akinori Yoda, Yuka Yoda, et al.
The American Journal of Surgical Pathology|January 2, 2007
Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphomaScott J Rodig, Kerry J Savage, Ann S LaCasce, et al.
The American Journal of Surgical Pathology|January 12, 2016
Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell DisordersJie Xu, Heather H Sun, Christopher D M Fletcher, et al.
Pageof 30

Showing results (71-80 of 293) with videos related to

Sort By:
Pageof 30
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 28, 2023
Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 TherapyElizabeth I Buchbinder, Kathleen L Pfaff, Madison M Turner, et al.
American Journal of Clinical Pathology|February 3, 2016
MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical PracticeMichael J Kluk, Caleb Ho, Hongbo Yu, et al.
Cancer Cell|August 18, 2012
Synergy between PI3K signaling and MYC in Burkitt lymphomagenesisSandrine Sander, Dinis P Calado, Lakshmi Srinivasan, et al.
Plos One|April 19, 2012
Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomasMichael J Kluk, Bjoern Chapuy, Papiya Sinha, et al.
Cancer Medicine|October 18, 2016
A phase I trial of panobinostat (LBH589) in patients with metastatic melanomaNageatte Ibrahim, Elizabeth I Buchbinder, Scott R Granter, et al.
Blood|August 21, 2012
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemiaChristopher J Ott, Nadja Kopp, Liat Bird, et al.
Haematologica|September 1, 2019
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomasLinfeng Chen, Jing Ouyang, Kirsty Wienand, et al.
Plos One|November 13, 2012
Next-generation cDNA screening for oncogene and resistance phenotypesNobuaki Shindoh, Akinori Yoda, Yuka Yoda, et al.
The American Journal of Surgical Pathology|January 2, 2007
Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphomaScott J Rodig, Kerry J Savage, Ann S LaCasce, et al.
The American Journal of Surgical Pathology|January 12, 2016
Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell DisordersJie Xu, Heather H Sun, Christopher D M Fletcher, et al.
Pageof 30